Stay updated on EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page
- Check2 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedFooter now shows Revision: v3.4.2, and older notices about government funding and operating status have been removed.SummaryDifference0.5%

- Check38 days agoChange DetectedA new site-wide notice warns that information may not be up to date due to a lapse in government funding, with guidance to check cc.nih.gov and opm.gov for updates. The page revision also updates to Revision: v3.4.1.SummaryDifference0.5%

- Check45 days agoChange DetectedMinor UI/text updates include a new 'Show glossary' option, capitalization/phrase tweaks (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and the site revision 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check59 days agoChange DetectedThe update is a site revision: Revision: v3.3.4 added and Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page now uses a consolidated Locations section listing Florida, Michigan, Oregon, and Texas, replacing the previous per-location pages. The HHS Vulnerability Disclosure link was removed from the footer, and the page version updated to v3.3.3.SummaryDifference0.6%

Stay in the know with updates to EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.